Workflow
Personalized Health Innovation
icon
Search documents
Hemostemix Granted Trademark "KNOW YOUR HEALTH" in Japan, International Registration No. 1744775 Covers Stem Cell Preparations and Research in Classes 1, 5, 42
Newsfile· 2025-10-22 14:04
Core Viewpoint - Hemostemix Inc. has been granted the trademark "KNOW YOUR HEALTH" in Japan, enhancing its intellectual property and global branding strategy in regenerative medicine and personalized health innovation [2][3]. Trademark Grant Details - The trademark registration covers Classes 1, 5, and 42, which include chemicals for scientific research, pharmaceutical preparations, and technological services in regenerative medicine [6]. - The registration number is International Registration No. 1744775, issued by the Japanese Patent Office [6]. Strategic Significance - The trademark aligns with Hemostemix's clinical programs, particularly the ACP-01 treatment for various ischemic and cardiopulmonary diseases, reinforcing the synergy between brand identity and product pipeline [5]. - The registration strengthens Hemostemix's global intellectual property portfolio, particularly in Japan, a leading market for medical research [10]. - The trademark allows for expanded therapeutic coverage, reflecting Hemostemix's leadership in developing autologous cell-based treatments for vascular and degenerative disorders [10]. - It provides a platform for global collaboration, enabling licensing and commercialization of innovations within Japan's regulatory framework for regenerative medicine [10]. CEO Commentary - The CEO expressed honor at the trademark grant, highlighting its importance for the company's commitment to improving patient health through autologous stem-cell therapy and enhancing partnerships with institutions in Asia [7]. Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, known for its VesCell™ (ACP-01) treatment, which has shown significant clinical results in various studies [8]. - The company has completed seven clinical studies involving 318 subjects, demonstrating the safety and efficacy of ACP-01 for treating multiple ischemic conditions [8].